Stocktoria
INTERPACE BIOSCIENCES, INC. IDXG
OTC · OOTC · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1998-05-19
INTERPACE BIOSCIENCES, INC. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.7M | $46.9M | $40.0M | $31.8M | $33.1M | $32.4M | $24.2M | $21.9M | $15.9M | $13.1M |
| Gross profit | $24.1M | $29.9M | $25.1M | $18.2M | $18.8M | $10.7M | $8.3M | $11.7M | $8.5M | $6.4M |
| R&D expense | $642,000 | $676,000 | $636,000 | $703,000 | $1.5M | $2.8M | $2.8M | $2.1M | $1.5M | $1.6M |
| Operating income | $4.1M | $8.1M | $4.0M | -$3.6M | -$6.3M | -$26.1M | -$26.4M | -$12.1M | -$6.3M | -$6.4M |
| Interest expense | — | — | — | — | — | $549,000 | $440,000 | $331,000 | $433,000 | — |
| Income tax | -$21.2M | $4,000 | $17,000 | $29,000 | -$705,000 | $53,000 | -$28,000 | $18,000 | -$395,000 | -$162,000 |
| Net income | $24.6M | $6.7M | $2.0M | -$22.0M | -$14.9M | -$26.5M | -$26.7M | -$12.2M | -$12.2M | -$8.3M |
| EPS (diluted) | $0.89 | $0.40 | $0.45 | $-5.18 | — | — | — | — | — | — |
| Operating cash flow | $5.8M | $4.6M | $3.8M | -$7.7M | -$8.7M | -$14.0M | -$19.0M | -$8.7M | -$15.3M | -$7.6M |
| Free cash flow | $5.5M | $3.8M | $3.3M | -$8.0M | -$9.1M | -$15.6M | -$19.1M | -$9.1M | -$15.3M | — |
| Cash & equivalents | $2.5M | $1.5M | $3.5M | $4.8M | $2.7M | $2.8M | $2.3M | $6.1M | $15.2M | $602,000 |
| Inventory | $1.1M | $1.2M | $1.2M | $1.2M | $825,000 | $2.1M | $1.8M | — | — | — |
| Total assets | $33.8M | $14.8M | $13.1M | $16.0M | $38.4M | $45.7M | $51.5M | $48.4M | $53.6M | $41.8M |
| Total liabilities | $11.5M | $17.0M | $22.1M | $32.5M | $34.3M | $28.2M | $29.8M | $15.5M | $13.7M | $35.2M |
| Shareholders' equity | $22.4M | -$2.2M | -$55.5M | -$58.1M | -$42.4M | -$29.1M | -$4.5M | $15.4M | $39.9M | $39.9M |
Growth · year-over-year · Revenue CAGR 12.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -17.5% | +17.2% | +25.7% | -3.9% | +2.2% | +33.8% | +10.6% | +37.7% | +21.5% | +38.7% |
| Net income growth | +266.7% | +243.0% | — | — | — | — | — | — | — | — |
| EPS growth | +122.5% | -11.1% | — | — | — | — | — | — | — | — |
| Free cash flow growth | +45.2% | +13.6% | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001054102 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.